Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -2.29.

EBIT: As of FY2025, the actual value is USD -129.6 M.

Operational Metrics

• Net Loss: The net loss for the fiscal year ended October 31, 2025, was $117.3 million, compared to $55.1 million for the fiscal year ended October 31, 2024.
• Research and Development Expenses: Increased by $56.2 million from $38.3 million for the year ended October 31, 2024, to $94.5 million for the year ended October 31, 2025.
• General and Administrative Expenses: Increased by $4.7 million from $24.0 million for the year ended October 31, 2024, to $28.7 million for the year ended October 31, 2025.

Cash Flow

• Net Cash Used in Operating Activities: $99.2 million for the fiscal year ended October 31, 2025, compared to $48.3 million for the fiscal year ended October 31, 2024.
• Net Cash Used in Investing Activities: $25.1 million for the fiscal year ended October 31, 2025, compared to $126.0 million for the fiscal year ended October 31, 2024.
• Net Cash Provided by Financing Activities: $1.5 million for the fiscal year ended October 31, 2025, compared to $265.7 million for the fiscal year ended October 31, 2024.

Unique Metrics

• Hercules Loan Agreement: As of October 31, 2025, the company had borrowed $22.5 million under the Amended Loan Agreement with Hercules Capital, Inc., with an effective interest rate of 11.63%.

Outlook / Guidance

• The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the ongoing LEGEND study of detalimogene, including the pivotal cohort of patients with BCG-unresponsive NMIBC, to completion; execute on its plan to file a Biologics License Application with the FDA in the second half of 2026; and pursue potential pipeline expansion via additional detalimogene development opportunities and other compounds.